Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy

NCT05403385 is registered in ClinicalTrials.gov with iTeos Therapeutics as lead sponsor.

NCT NCT05403385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05403385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy
Lead sponsor
iTeos Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 26, 2022
Completion date
October 31, 2025
Enrollment
36 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced nsclc - non-small cell lung cancer, metastatic nsclc - non-small cell lung cancer